AT7519 Hydrochloride
Based on 18 publication(s) in Google Scholar
AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.16%
- CAS. Nr.: 902135-91-5
- Formel: C16H18Cl3N5O2
- Molecular Weight:418.71
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10008
SNS-032CDK Inhibitor -
HY-10014
R547CDK Inhibitor -
HY-11001
PHA-793887Cyclin-dependent Kinase Inhibitor -
HY-10005
FlavopiridolCDK Inhibitor -
HY-10012
AZD-5438CDK1/2/9 Inhibitor -
HY-10182A
Laduviglusib monohydrochlorideGSK-3α/β Inhibitor -
HY-10006
Flavopiridol HydrochlorideCDK Inhibitor -
HY-16297R
Abemaciclib methanesulfonate (Standard)CDK4/6 Inhibitor -
HY-18340A
(R)-CR8 trihydrochloride -
HY-15504A
RGB-286638 free baseCDK/MAPK9 Inhibitor -
HY-50943R
AT7519 Hydrochloride (Standard)CDK Inhibitor -
HY-12529
Ro-3306CDK1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) AT7519 Hydrochloride
More- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Adv Sci (Weinh). 2024 Mar;11(11):e2305260. [Abstract]
- Cell Rep Med. 2026 May 14:102819. [Abstract]
- Oncogene. 2023 Nov;42(47):3503-3513. [Abstract]
- Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5. [Abstract]
- EMBO Mol Med. 2025 Nov 26. [Abstract]
- Sci Rep. 2021 Mar 8;11(1):5374. [Abstract]
- FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]
- FEBS J. 2026 May 4. [Abstract]
- RNA Biol. 2021 Nov 12;18(sup2):722-729. [Abstract]
- Mol Carcinog. 2025 Dec 2. [Abstract]
- Glycobiology. 2022 Aug 18;32(9):751-759. [Abstract]
- Exp Eye Res. 2023 Feb:227:109391. [Abstract]
- PLoS One. 2025 Jun 17;20(6):e0324443. [Abstract]
- Dev Biol. 2024 Apr:508:93-106. [Abstract]
- SSRN. 2026 May 20.
- bioRxiv. 2025 Nov 17.
- bioRxiv. 2024 September 07.
Customer Validation & Images
-
WB
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
IP
-
WB
Biologische Aktivität
Beschreibung
IC50 & Target
[2]|
CDK9/Cyclin T 10 nM (IC50) |
CDK5/p35 13 nM (IC50) |
cdk2/cyclin A 47 nM (IC50) |
Cdk4/cyclin D1 100 nM (IC50) |
cdk6/cyclin D3 170 nM (IC50) |
Cdk1/cyclin B 210 nM (IC50) |
CDK7/Cyclin H/MAT1 2400 nM (IC50) |
GSK3β 89 nM (IC50) |
In Vitro
AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells[1]. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines[2]. AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 902135-91-5
-
Appearance Solid
-
Molecular Weight 418.71
-
Formel C16H18Cl3N5O2
-
Color White to off-white
-
SMILES
O=C(C(C(Cl)=CC=C1)=C1Cl)NC2=CNN=C2C(NC3CCNCC3)=O.[H]Cl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Adv Sci (Weinh)
SHMT2 Mediates Small-Molecule-Induced Alleviation of Alzheimer Pathology Via the 5'UTR-dependent ADAM10 Translation Initiation. [Abstract]2024 Mar;11(11):e2305260. PMID: 38183387
AT7519 Hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(11):e2305260. [Abstract]
Chemical structure of another CDK/GSK inhibitor AT7519 (top), and immunoblots (middle) and quantification (bottom) of ADAM10 in SH‐SY5Y cells treated with AT7519 (1 to 20 µM for 36 h, n = 5)
-
Cell Rep Med
Artificial exosomes synergistically reshape sepsis immune homeostasis by modulating neutrophil fate and blocking PD-1/PD-L1. [Abstract]2026 May 14:102819. PMID: 42140195 -
Oncogene
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. [Abstract]2023 Nov;42(47):3503-3513. PMID: 37845392
AT7519 Hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Nov;42(47):3503-3513. [Abstract]
Western blot analysis of the levels of pGSK3β (S9), GSK3β and EGFR in A549 and PC9 cells treated with AT7519 (0.5 μM, 30 h), DIF-3 (30 μM, 30 h) and D-mannose (25 mM, 24 h) as indicated.
-
Cell Chem Biol
2018 Feb 15;25(2):135-142.e5. PMID: 29276047 -
EMBO Mol Med
Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]2025 Nov 26. PMID: 41299101 -
Sci Rep
2021 Mar 8;11(1):5374. PMID: 33686114 -
FASEB J
2024 Apr 30;38(8):e23628. PMID: 38661032
AT7519 Hydrochloride purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]
RT-qPCR data analysis showing the on-target effect of CDK9 inhibition (500 nM AT7519 for 4 h) on MYC mRNA.
AT7519 Hydrochloride purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]
Cell viability was measured using CellTiter-Glo after 4 days of treatment with mTOR inhibitor (everolimus) in the presence or absence of AT7519 (LNCaP and C4-2: 0.5 μM; 22RV1: 2 μM).
AT7519 Hydrochloride purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]
LNCaP cells were treated with a CDK9 inhibitor (500 nM AT7519) for 4 h, and wheat germ agglutinin (WGA)-lectin pulldown was used to enrich for proteins O-GlcNAcylated in the given conditions. The data are representative of two biological replicates; OGT is used as a positive control andactin as a negative control in the pulldown samples. For clarity, both long- and short- exposure Western blots of MAVS antibody are shown. Densitometry was used to determine the signal intensities.
-
FEBS J
CDK14 is a critical regulator of haematopoietic stem and progenitor cell maintenance and post-transplantation proliferation. [Abstract]2026 May 4. PMID: 42080702 -
RNA Biol
2021 Nov 12;18(sup2):722-729. PMID: 34592899 -
Mol Carcinog
Purvalanol A Exerts Anti-Hepatocellular Carcinoma Activity by Activating the p53 Pathway. [Abstract]2025 Dec 2. PMID: 41328606 -
Glycobiology
2022 Aug 18;32(9):751-759. PMID: 35708495 -
Exp Eye Res
2023 Feb:227:109391. PMID: 36696946 -
PLoS One
2025 Jun 17;20(6):e0324443. PMID: 40526635 -
Dev Biol
Neutrophils facilitate the epicardial regenerative response after zebrafish heart injury. [Abstract]2024 Apr:508:93-106. PMID: 38286185 -
-
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 300 mg/mL (716.49 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 8.33 mg/mL (19.89 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36. [Content Brief]
[2]. Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [Content Brief]
[3]. Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.3883 mL | 11.9414 mL | 23.8829 mL | 59.7072 mL |
| 5 mM | 0.4777 mL | 2.3883 mL | 4.7766 mL | 11.9414 mL | |
| 10 mM | 0.2388 mL | 1.1941 mL | 2.3883 mL | 5.9707 mL | |
| 15 mM | 0.1592 mL | 0.7961 mL | 1.5922 mL | 3.9805 mL | |
| DMSO | 20 mM | 0.1194 mL | 0.5971 mL | 1.1941 mL | 2.9854 mL |
| 25 mM | 0.0955 mL | 0.4777 mL | 0.9553 mL | 2.3883 mL | |
| 30 mM | 0.0796 mL | 0.3980 mL | 0.7961 mL | 1.9902 mL | |
| 40 mM | 0.0597 mL | 0.2985 mL | 0.5971 mL | 1.4927 mL | |
| 50 mM | 0.0478 mL | 0.2388 mL | 0.4777 mL | 1.1941 mL | |
| 60 mM | 0.0398 mL | 0.1990 mL | 0.3980 mL | 0.9951 mL | |
| 80 mM | 0.0299 mL | 0.1493 mL | 0.2985 mL | 0.7463 mL | |
| 100 mM | 0.0239 mL | 0.1194 mL | 0.2388 mL | 0.5971 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
AT7519 Hydrochloride Related Classifications
HY-50943 Related Classifications
Powered by Bioz